An immunohistochemical evaluation of phosphorylated Akt at threonine 308 [pAkt(Thr308)] in invasive breast cancer

In Vivo

Volumn 21, Issue 6, 2007, Pages 967-972

  Magkou, C ^a   Mylona, E ^a   Theohari, I ^b   Giannopoulou, I ^a   Papanikolaou, E ^d   Markaki, S ^c   Nakopoulou, L ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Breast cancer; cerbB 2; Ki 67; Lobular; p53; pAkt(Thr308)

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P53; THREONINE;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INVASION; CANCER SIZE; CANCER STAGING; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 37349057962     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Testa JR and Belacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
2. Datta SR, Brunet A and Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
3. Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Guroya K, Gudkov A and Testa JR: AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21(22): 3532-3540, 2002.
4. Luo J, Manning BD and Cantley LC: Targeting the P13K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262, 2003.
5. Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M and Winters ZE: Activated Akt expression in breast cancer: Correlation with p53, Hdm2 and patient outcome. Eur J Cancer 41: 1017-1025, 2005.
6. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the Akt/mammalian target of rapamycin/ 4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancer. Clin Cancer Res 10: 6779-6788, 2004.
7. Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW and Baba HA: Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17: 15-21, 2004.
8. Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikabe M, Kakeji Y, Baba H and Maehara Y: Akt is frequently activated in Her2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118: 284-89, 2006.
9. Tavassoli FA and Davilee P: Tumors of the breast and female genital organs. Classification of tumors No 4. Lyon: IARC, WHO 2003.
10. Robins P, Pinder S and de Klerk N: Histological grading of breast carcinomas: a study of interobserved agreement. Human Pathol 28: 870-873, 1995.
11. Union International Contre Cancer. TNM Classification of International Union against Cancer. Hermanek P and Sabin H (eds.). TNM Atlas. 4th ed, 3rd revision. Berlin: Springer-Verlag, 1992.
12. McCleilland RA, Wilson D, Leake R, Finlay P and Nicholson RI: A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 27: 711-716, 1991.
13. Nakopoulou L, Lazaris AC, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A and Davaris P: DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 68: 137-143, 2000.
14. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A and Bartlett JMS: Akt activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139-146, 2007.
15. Xia W, Chen J-S, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP and Hung M-C: Phosphorylation/Cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer. Clin Cancer Res 10: 3815-3824, 2004.
16. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JFR and Ellis IO: The role of PTEN and its signalling pathways, including AKT in breast cancer; an assessment of relationships with other prognostic factors and outcome. J Pathol 204: 93-100, 2004.
17. Stal O, Perez-Tenorion G, Akerberg L, Olsson B, Nordenskjold B, Skoog L and Rutqvist LS: Akt kinases in breast cancer and the results of adjuvant therapy. Br Cancer Res 5: 37-44, 2003.
18. Schmitz KJ, Grabellus F, Callies R, Wohischlaeger J, Otterbach F, Kimmig R, Levkau B, Schmid KW and Baba H: Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression. Virchows Arch 448: 16-23, 2006.
19. Giancotti V: Breast cancer markers. Cancer Lett 243: 145-159, 2006.
20. Zhou BP, Dent J, Xia W, Xu J, Li XM, Gunduz M and Hung MC: Dual regulation of Snail by GSK-3β-mediated phosphrylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6: 931-940, 2004.
21. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC: HER-2/neu induces ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982, 2001.